MB-1

N/A

Report date: 2025/06/11 11:07:35
NME

Base Information

Drug NameMB-1
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionInterleukin-23 inhibitors
TargetsInterleukin-23
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Washington
China Registration ClassN/A

Develop Information

Active CompaniesLudwig-Maximilians-Universität MünchenMopac Biologics IncStanford University +[4] 
Inactive CompaniesN/A
Active IndicationsInflammatory Bowel Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A